Doylestown, Pennsylvania--(Newsfile Corp. - September 3, 2026) - Mid-Atlantic BioTherapeutics, Inc. (MABT), a pharmaceutical company focused on the clinical development and commercialization of novel therapeutic approaches using AI-enabled technologies, is pleased to announce its participation at the upcoming Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9-10, 2026, in New York City. David Horn, M.D., Chief Executive Officer, will be attending the conference, delivering an investor presentation and participating in scheduled 1-on-1 meetings with investors.

Date: Thursday, September 10, 2026
Time: 9:30 am EDT
Location: The Westin New York Grand Central, 212 E 42nd St, New York, NY
Presenter: David Horn, M.D., Chief Executive Officer
More info: https://moodycapital.com/conference/

"We're excited to bring Mid-Atlantic BioTherapeutics' pipeline to the investment community at this year's Disruptive Growth & Life Sciences Conference. Since acquiring XPose Therapeutics earlier this year, we've built a differentiated portfolio spanning our clinical-stage IMT504 immunotherapy platform and a growing set of DNA damage response (DDR) programs targeting APE1, PARP1, and others, enabled by our AI Drug Discovery platform & partnerships. We look forward to sharing our progress and connecting with investors who share our commitment to advancing novel therapies for patients with few options in oncology and CNS disease."

- David Horn, M.D., Chief Executive Officer, Mid-Atlantic BioTherapeutics

About the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

The Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference brings together public and private growth companies, pioneering innovators, investors, C-suite executives and industry professionals across biotechnology, medical devices, pharmaceuticals, healthcare technology and other growth industries. The two-day conference features company presentations, one-on-one investor meetings, fireside chats, capital markets and financing panels, and networking opportunities with institutional investors and family offices.

About Mid-Atlantic BioTherapeutics, Inc.

We are a pharmaceutical company focused on the clinical development and commercialization of novel therapeutic approaches and AI-enabled technologies. Our scientific and medical focus is on oncology and CNS disorders, targeting diseases such as ovarian, breast, lung, and adult and pediatric brain cancers, viral encephalitis, Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis (ALS).

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312594

Source: Moody Capital Solutions